Lower urinary tract symptoms and prostatic growth pattern among old and middle-aged males in Shanghai community / 中华男科学杂志

<p><b>OBJECTIVE</b>To investigate the prevalence of lower urinary tract symptoms (LUTS) and the age-related growth pattern of the prostate among 40 -70 year-old males in Shanghai community.</p><p><b>METHODS</b>Using cluster and stratified random sampling and IPSS, we investigated the prevalence of LUTS among 1000 males aged 40 -70 years in the general population of Shanghai from November 2009 to June 2010. We measured the transverse, anteroposterior and vertical diameters of the prostate and its transition zone in each volunteer by transrectal ultrasonography and established the equation for the age-related growth pattern of the prostate.</p><p><b>RESULTS</b>In the 40 to 49-, 50 to 59- and 60 to 70-year groups, the incidence rates of moderate and severe LUTS (IPSS > or = 8) were 10.0%, 15.0% and 28.7%, respectively. The length, width, height and volume of the prostate and its transition zone were positively corrected with age (P < 0.05). The prostatic growth pattern equations based on the parameters of the transverse, anteroposterior and vertical diameters were Y = 1.6 x 10(-5)X3-0.002 1X2 + 0.074 6X + 0.677 2, Y = -2.4 x 10(-5)X3 + 0.003 3X2-0.1312X + 1.269, and Y = 1.6 x 10(-5)X3-0.001 8X2 + 0.073X- 0.690 9, respectively. The transverse and anteroposterior diameters of the prostate grew at a relatively similar rate, while the transverse diameter grew obviously faster than the vertical diameter before 60 years old, but the latter significantly increased and even exceeded the former after 60 years old.</p><p><b>CONCLUSION</b>The prevalence of LUTS among old and middle-aged males in Shanghai community is similar to that recently reported at home and abroad. The transverse and anteroposterior diameters of the prostate grow at a relatively similar rate, but the vertical diameter increases faster after 60 years old.</p>

Polymorphism of AR gene CAG copy number and late-onset hypogonadism in males / 中华男科学杂志

<p><b>OBJECTIVE</b>To analyze the association of the androgen receptor (AR) gene CAG-STR with late-onset hypogonadism (LOH), and explore the pathogenesis of LOH.</p><p><b>METHODS</b>Our investigation involved 1 000 men aged 40-70 years. We randomly selected 127 normal old and middle-aged males and 19 cases of LOH. We detected their levels of Triglyceride (TG), fasting blood glucose (FBG), serum total testosterone (tT) and free testosterone (fT), measured their body mass index (BMI), height, waist circumference (WC) and blood pressure, and examined the length of CAG repeats of the AR gene in the peripheral blood by PCR.</p><p><b>RESULTS</b>The numbers of CAG repeats ranged from 15 to 32, with a mean value 23.05 +/- 2.95. The mean BMI and FBG were significantly lower (P < 0.01), but TG, tT and fT remarkably higher in the normal than in the LOH men (P < 0.01), while the mean length of (CAG) n repeat polymorphism showed no statistically significant difference between the two groups (22.54 +/- 3.06 vs 23.23 +/- 2.24, P = 0.946). The frequencies of long alleles (n > or = 22) were significantly higher in the LOH than in the normal men (73.68% vs 48.82%, P < 0.05). The numbers of CAG repeats had no significant correlation with tT (r = 0.04, P > 0.05) and fT (r = 0.025, P > 0.05).</p><p><b>CONCLUSION</b>The AR gene CAG length showed polymorphism in LOH men. The long alleles (CAG)n (n > or = 22) repeat polymorphism in the AR gene may be a genetic factor for LOH, but it has to be confirmed by further investigation.</p>

Safety and efficacy of tramadol hydrochloride with behavioral modification in the treatment of premature ejaculation / 中华男科学杂志

<p><b>OBJECTIVE</b>To evaluate the efficacy and safety of tramadol hydrochloride with behavioral modification in delaying ejaculation in patients with premature ejaculation.</p><p><b>METHODS</b>Seventy-two potent men with premature ejaculation were equally and randomly assigned to a treatment group and control group, the former received 50 mg tramadol hydrochloride with behavioral modification approximately 2 hours before planned sexual activity, while the latter underwent behavioral therapy only, both treated for 8 weeks. Intravaginal ejaculatory latency time (IELT), intercourse satisfaction of the partners, total therapeutic effectiveness, adverse reactions, and hepatic and renal function of the patients were recorded and compared before and after the treatment.</p><p><b>RESULTS</b>Both the treatment and the control groups showed significant differences from pretreatment in the mean IELT and intercourse satisfaction domain values (P < 0.01). The total rate of effectiveness was 72.2% in the treatment group and 47.2% in the control. The former exhibited even more significant improvement than the latter in the mean IELT, intercourse satisfaction domain values and total rate of effectiveness (P < 0.05). Adverse reactions occurred in 10 cases (27.8%), and no statistically significant differences were found in hepatic and renal function before and after treatment (P > 0.05).</p><p><b>CONCLUSION</b>Tramadol hydrochloride with behavioral modification showed positive effects in prolonging IELT and improving partners' intercourse satisfaction. Yet more multicenter and double-blind studies are required to evaluate its efficacy and safety as a routine therapy for premature ejaculation.</p>

Shenfu Qiangjing decoction improves non-inflammatory and non-liquefied semen in kidney-yang deficiency men / 中华男科学杂志

<p><b>OBJECTIVE</b>To observe the clinical efficacy of Shenfu Qiangjing Decoction (SQD) in the treatment of non-inflammatory and non-liquefied semen in infertile males with kidney-yang deficiency.</p><p><b>METHODS</b>Sixty cases of male infertility caused by non-inflammatory and non-liquefied semen with kidney-yang deficiency were equally and randomly divided into an SQD and a control group, the former given oral SQD and the latter vitamin C tablets plus intramuscular chymotrypsin. Both groups were observed for sperm viability, sperm motility, serum testosterone, seminal plasma PSA and improvement of kidney-yang deficiency symptoms before and after the medication. The therapeutic effects were evaluated according to the semen liquefaction within 60 min.</p><p><b>RESULTS</b>Statistically significant differences were observed in the improvement of kidney-yang deficiency symptoms after the medication between the SQD and control groups (P < 0.01, P < 0.05) , and in sperm viability and motility of the SQD group before and after the treatment (P < 0.01) as well as between the two groups after the medication (P < 0.05). The levels of serum T and seminal plasma PSA also showed significant differences before and after the treatment in the SQD group (P < 0.01) and between the two groups after the medication (P < 0.05). The rate of total effectiveness was 93.3% in the SQD and 76.7% in the control group (P < 0.05).</p><p><b>CONCLUSION</b>SQD can shorten the semen liquefaction time in patients with non-inflammatory and non-liquefied semen and restore semen liquefaction to normal in over 90% of the patients. Meanwhile it can also improve the low testosterone level resulting from various kidney-yang deficiency symptoms.</p>